TARS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Tarsus Pharmaceuticals (TARS) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock shows positive growth potential, supported by strong hedge fund buying, favorable analyst ratings, and a SwingMax signal. Despite short-term financial challenges, the company's revenue growth and strategic initiatives in the eye care market indicate long-term upside.
The MACD is positive and expanding (0.368), indicating bullish momentum. RSI is neutral at 57.131, and moving averages are converging, suggesting no immediate strong trend. The stock is trading near its resistance level (R1: 66.783), with pre-market price at $66. The technicals suggest moderate bullish sentiment.
Hedge fund buying increased by 987.14% last quarter, signaling institutional confidence.
Appointment of David E. I. Pyott to the Board of Directors to enhance growth in the eye care market.
SwingMax signal from 2026-02-11 indicates a buy-low opportunity.
Revenue growth of 146.68% YoY in Q3 2025.
Net income dropped by 46.26% YoY in Q3 2025, and EPS declined by 50.82%, reflecting profitability challenges.
High implied volatility and option volume put-call ratio suggest short-term uncertainty.
Neutral insider trading activity indicates lack of strong insider confidence.
In Q3 2025, revenue increased by 146.68% YoY to $118.7M, showing strong top-line growth. However, net income dropped to -$12.58M (-46.26% YoY), and EPS declined to -0.3 (-50.82% YoY), indicating profitability challenges. Gross margin remained high at 93%, down slightly by 0.28% YoY.
Goldman Sachs raised the price target to $68 from $51 with a Neutral rating, while Barclays initiated coverage with an Overweight rating and a $100 price target, citing easing pricing headwinds and sector transition opportunities. Analyst sentiment is moderately positive with room for growth.
